Mary McGovern Presents Adtec Healthcare at LSI Europe '23

Transcription

Mary McGovern  0:05  
Good morning, everybody. I'm Mary from Adtech Healthcare. And I'd like to introduce you to our code plasma, our clinical evidence, and also our business plan. We're based in London, UK, we are a CE marked medical device company. We come from a larger industrial company, we're a spin out. So as we may or may not know, plasma is used in the semiconductor industry to make semiconductor devices. So your phone, or your screens or your computers, all this high tech uses plasma, plasma is an energized gas and what we make as cold plasma. We were the first company in the world to introduce premium cold plasma to treat chronic wounds. We own the IP, which is microwave plasma. We have 75, peer reviewed clinical studies all in journals, we're looking to raise 15 million. With this we hope to go to expand our business and to go to the States with FDA approval. So what is the problem we're addressing? The problem is infected wounds. As you may know, with an infected wound, if it's not treated, it can lead to amputation, it can lead to sepsis. It is very serious problem in the world. And as you may remember, when COVID started when there was no vaccine, it was a very scary position. And there was another threat with antimicrobial resistance. Who has declared that AMR is one of the greatest public threats, it's called the silent pandemic. It will there are already some bacteria clever, they become resistant to antibiotics. So it's very important to use alternative antibiotic anti microbials whenever possible. And also bacteria being clever like virus have generated biofilms this biofilm is like a house it around the bacteria and it makes it 1000 times more resistant to antibiotics. So what we are the plasma which I mentioned earlier plasma is often called the fourth state of matter. It's when you apply energy to a gas, you will get plasma, the Northern Lights Aurora are quite pretty plasma. Also around the Sun is plasma. What will we have generated is what we call cold compared to hot so it's about 40 degrees. So therefore it's mild enough to treat wounds treat the patient. So this plasma includes UV it includes reactive oxygen species reactive nitrogen species, ions, radicals, electrons, and UV light. And they all combined together to create a physical hole in the bacterial cell wall. So it's a physical mode of action rather than a chemical mode of action. This has great advantage for not developing resistance. And as I said, we were the first company in the world to treat cold plasma. So about the story plus this is our device. We have proven efficacy. We have done eight clinical trials. We've also have a number of clinical studies and journals published in Europe, we have shown the foster healing. Now it's a two minute treatment once or twice a week for a few weeks. It's placed on top of the wound, particularly for diabetic foot ulcers, the blood flow is perfusionists is difficult. And the antibiotics don't always reach the toes. So if the toes and if the infection goes into the bone, it'll go into osteoporosis. So our device is mobile, it can be moved around the clinic to different parts. It's a two minute treatment, you can see 2030 patients a day. We have thankfully had no side effects or adverse events since the start. Of course, this is based on our design. So our main clinical efficacy, where we looked at most of our data is gathered from so far is diabetic foot ulcers. We have a clinic in the UK that's using our product every day, treating many patients and also preventing amputation. surgical site infection is also another big problem. Usually after surgery patients are pumped with antibiotics, but in some cases it does go on that infection is generated. So here you can see where we treat deep sternum wounds. So the plasma is placed over the wound, two minute, two minute, two minutes. We also have indications in dermatology, obviously with any bacterial conditions such as acne, and we did a clinical trial on actinic keratosis, which is pre scan cancer skin lesions. So as I said, This certifies our efficacy on our premium Cold Plasma, particularly on biofilm. So we did our biofilm in the laboratories as well as in our clinical studies. So in a laboratory, a 24 hour biofilm, 72 hour biofilm. We've shown that the bacterial load reduction was to zero after five minutes treatment. So biofilms is in the world In the industry, it's a it's everybody is talking about it. But also another potential indication is an implants. So when an implant is put put in the body like a knee or hip implants it biofilms and infection is introduced during surgery. And this can lead to big complications where often the implant has to be removed again. So plasma as a gas, it moves it travels. And it will be we envision it's putting the plasma over the implant during surgery. One of our particular strong indications where we've had a lot of traction is an LVAD drive line infection. So an LVAD is an external pump. And the drive line is often infected, the drive line is usually here, and the body and the biofilm and bacteria generate around the drive line, which of course is very difficult to treat with antibiotics. And up to 30% of drive lines get infected. So we had a number of our clinicians I remember my first doctor, I met in Muenster, Germany, a cardiac surgeon, I was saying, oh, plasma can move it can, you know, go down hair follicles, he's got a hard drive lines. So he was the first to use it on Dr lens and has great efficacy as the plasma, we will move down the drive line. So he has this is some of the data he produced, where they completely healed within one or two weeks. And of course, because it's a physical mode of action, it does not matter what type of bacteria is a gram positive gram negative co plasmas, it has the efficacy against all of these. So we've had a number of other like in Vienna, they're also University Hospital in Vienna, is also using our study pass every day on the the LVAD coordinator has presented, I think, at four conferences this year, all with the great data that he has shown from using our device. So as I said, we're clinically proven the chronic wounds. So we were when we were the first in the world, we worked with the Max Planck Institute in Germany, which was fantastic, because we had a lot of good scientific research, and Max Planck. So our first clinical trials were comparing standard of care with antibiotics, and then standard of care with antibiotics and plasma. And we showed that we were able to reduce the bacterial load 50% More than the standard of care. And then the diabetic foot ulcers, we've also done a clinical trial where we took biopsies, and therefore we could measure the change in the bacteria load over the four week treatment. And we have shown that the plasma side had improved efficacy versus the standard of care, the LVAD infections, we've not done a clinical trial, but we do have a lot of clinical evidence. And we have shown that we've been able to manage the infection in the patients, and therefore they did not need to get in research because often the LVAD, which costs hundreds of 1000s would have to be taken out again, lead extraction and starting over again. And also the LVAD patients there. There's not as many heart donors. So sometimes LVAD is now people live with it for a number of years. So as you may, you may know, the wound care market is big, the surgical site infection is big. So it's a 20 billion market. But we are with our clinical efficacy and using treating an infection. We believe we have a great potential. Where are we today we're CE approved. We have approval in Taiwan as well and some other regions and we do not have FDA approval. However, we went to a conference this year and LVAD conference, and we have over 40 clinics wanting to test our device. Unfortunately for us, we don't have FDA approval. So it's quite sad, but that are waiting and we will work with them. Once we do. The timeline, we started the clinical trials in 2005. And then in 2014, I decided to become a medical device company. And this is when we designed a study plan. And we're now looking so we spun off from the industrial plasma company this year as a separate entity because we really want to work with a medical company and work with investors. This is the team may I have a lot of experience in business development. I started in the industrial provident semiconductor. I did the first sales for ad tech in America in Europe. Francois, our South African Chief Technology Officer is very strong in plasma and product design and J their business development has a lot of great relationships with KOLs. Thank you.